TNF Pharmaceuticals, Inc. (TNFA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, TNF Pharmaceuticals, Inc. (TNFA) has a cash flow conversion efficiency ratio of -0.178x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.07 Million) by net assets ($11.60 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See TNF Pharmaceuticals, Inc. (TNFA) liquidity interval to measure how many days the company can operate on defensive assets alone.
TNF Pharmaceuticals, Inc. - Cash Flow Conversion Efficiency Trend (2004–2024)
This chart illustrates how TNF Pharmaceuticals, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
TNF Pharmaceuticals, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of TNF Pharmaceuticals, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SINTEZA S.A.
RO:STZ
|
N/A |
|
DGB Group NV
AS:DGB
|
0.235x |
|
MEDAPP S.A. ZY -10
F:WQ1
|
0.076x |
|
Sahakol Equipment Public Company Limited
BK:SQ
|
0.164x |
|
The GrowHub Limited Class A Ordinary Shares
NASDAQ:TGHL
|
0.869x |
|
Platina Resources Limited
F:P4R
|
-0.023x |
|
Transocean Holdings Bhd
KLSE:7218
|
-0.015x |
|
Compass Group PLC
LSE:CPG
|
0.258x |
Annual Cash Flow Conversion Efficiency for TNF Pharmaceuticals, Inc. (2004–2024)
The table below shows the annual cash flow conversion efficiency of TNF Pharmaceuticals, Inc. from 2004 to 2024. For the full company profile with market capitalisation and key ratios, see TNFA stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $14.72 Million | $-8.98 Million | -0.610x | +39.99% |
| 2023-12-31 | $12.77 Million | $-12.98 Million | -1.016x | -21.70% |
| 2022-12-31 | $14.70 Million | $-12.27 Million | -0.835x | -1.17% |
| 2021-12-31 | $23.65 Million | $-19.52 Million | -0.825x | -511.96% |
| 2020-12-31 | $34.58 Million | $-4.66 Million | -0.135x | +58.96% |
| 2019-12-31 | $9.36 Million | $-3.07 Million | -0.329x | +77.49% |
| 2018-12-31 | $5.83 Million | $-8.52 Million | -1.460x | -117.05% |
| 2017-12-31 | $7.55 Million | $-5.08 Million | -0.673x | +45.40% |
| 2016-12-31 | $3.39 Million | $-4.17 Million | -1.232x | -58.49% |
| 2015-12-31 | $6.60 Million | $-5.13 Million | -0.777x | -196.31% |
| 2014-12-31 | $14.81 Million | $-3.88 Million | -0.262x | +60.39% |
| 2013-12-31 | $4.12 Million | $-2.73 Million | -0.662x | -173.81% |
| 2012-12-31 | $4.30 Million | $-1.04 Million | -0.242x | +34.04% |
| 2011-12-31 | $6.17 Million | $-2.26 Million | -0.367x | -36.69% |
| 2010-12-31 | $6.45 Million | $-1.73 Million | -0.268x | -39.14% |
| 2009-12-31 | $7.18 Million | $-1.38 Million | -0.193x | -522.17% |
| 2008-12-31 | $10.28 Million | $469.37K | 0.046x | +111.11% |
| 2007-12-31 | $-443.38K | $182.19K | -0.411x | -120.67% |
| 2006-12-31 | $-2.67 Million | $-5.31 Million | 1.988x | +210.63% |
| 2005-12-31 | $3.12 Million | $-5.61 Million | -1.797x | -222.55% |
| 2004-12-31 | $-2.79 Million | $-4.10 Million | 1.466x | -- |
About TNF Pharmaceuticals, Inc.
Q/C Technologies, Inc., a clinical-stage pharmaceutical company, focuses on developing and commercializing therapeutic platforms based on various therapeutic targets. The company develops Isomyosamine, a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including sarcopenia, frailty, adverse effects of drugs used to treat diabetes and obesity, rh… Read more